FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3140860453> ?p ?o ?g. }

• W3140860453 endingPage "440" @default.
• W3140860453 startingPage "428" @default.
• W3140860453 abstract "Tepotinib is a highly selective and potent MET inhibitor in development for the treatment of patients with solid tumors. Given the favorable tolerability and safety profiles up to the maximum tested dose in the first-in-human (FIH) trial, an efficacy-driven translational modeling approach was proposed to establish the recommended phase II dose (RP2D). To study the in vivo pharmacokinetics (PKs)/target inhibition/tumor growth inhibition relationship, a subcutaneous KP-4 pancreatic cell-line xenograft model in mice with sensitivity to MET pathway inhibition was selected as a surrogate tumor model. Further clinical PK and target inhibition data (derived from predose and postdose paired tumor biopsies) from a FIH study were integrated with the longitudinal PKs and target inhibition profiles from the mouse xenograft study to establish a translational PK/pharmacodynamic (PD) model. Preclinical data showed that tumor regression with tepotinib treatment in KP-4 xenograft tumors corresponded to 95% target inhibition. We therefore concluded that a PD criterion of sustained, near-to-complete (>95%) phospho-MET inhibition in tumors should be targeted for tepotinib to be effective. Simulations of dose-dependent target inhibition profiles in human tumors that exceeded the PD threshold in more than 90% of patients established an RP2D of tepotinib 500 mg once daily. This translational mathematical modeling approach supports an efficacy-driven rationale for tepotinib phase II dose selection of 500 mg once daily. Tepotinib at this dose has obtained regulatory approval for the treatment of patients with non-small cell lung cancer harboring MET exon 14 skipping." @default.
• W3140860453 created "2021-04-13" @default.
• W3140860453 creator A5005542807 @default.
• W3140860453 creator A5005665121 @default.
• W3140860453 creator A5012553792 @default.
• W3140860453 creator A5021088641 @default.
• W3140860453 creator A5023543619 @default.
• W3140860453 creator A5026095888 @default.
• W3140860453 creator A5036477513 @default.
• W3140860453 creator A5068640051 @default.
• W3140860453 creator A5069777765 @default.
• W3140860453 date "2021-05-01" @default.
• W3140860453 modified "2023-10-11" @default.
• W3140860453 title "Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose" @default.
• W3140860453 cites W178430551 @default.
• W3140860453 cites W1971029368 @default.
• W3140860453 cites W1994912526 @default.
• W3140860453 cites W1997407706 @default.
• W3140860453 cites W2019573100 @default.
• W3140860453 cites W2040143488 @default.
• W3140860453 cites W2062126586 @default.
• W3140860453 cites W2066852162 @default.
• W3140860453 cites W2074642772 @default.
• W3140860453 cites W2077981051 @default.
• W3140860453 cites W2085063569 @default.
• W3140860453 cites W2103633410 @default.
• W3140860453 cites W2107763333 @default.
• W3140860453 cites W2116780606 @default.
• W3140860453 cites W2132658857 @default.
• W3140860453 cites W2151729293 @default.
• W3140860453 cites W2154905847 @default.
• W3140860453 cites W2155238158 @default.
• W3140860453 cites W2160725767 @default.
• W3140860453 cites W2165135596 @default.
• W3140860453 cites W2177389390 @default.
• W3140860453 cites W2182630921 @default.
• W3140860453 cites W2279897843 @default.
• W3140860453 cites W2342166807 @default.
• W3140860453 cites W2562169753 @default.
• W3140860453 cites W2588681261 @default.
• W3140860453 cites W2591724635 @default.
• W3140860453 cites W2750691704 @default.
• W3140860453 cites W2765258454 @default.
• W3140860453 cites W2766126886 @default.
• W3140860453 cites W2789329449 @default.
• W3140860453 cites W2789873517 @default.
• W3140860453 cites W2890036337 @default.
• W3140860453 cites W2947129619 @default.
• W3140860453 cites W2969837032 @default.
• W3140860453 cites W2995360881 @default.
• W3140860453 cites W3013025907 @default.
• W3140860453 cites W3029971508 @default.
• W3140860453 cites W3031018272 @default.
• W3140860453 doi "https://doi.org/10.1002/psp4.12602" @default.
• W3140860453 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8129711" @default.
• W3140860453 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33818908" @default.
• W3140860453 hasPublicationYear "2021" @default.
• W3140860453 type Work @default.
• W3140860453 sameAs 3140860453 @default.
• W3140860453 citedByCount "12" @default.
• W3140860453 countsByYear W31408604532022 @default.
• W3140860453 countsByYear W31408604532023 @default.
• W3140860453 crossrefType "journal-article" @default.
• W3140860453 hasAuthorship W3140860453A5005542807 @default.
• W3140860453 hasAuthorship W3140860453A5005665121 @default.
• W3140860453 hasAuthorship W3140860453A5012553792 @default.
• W3140860453 hasAuthorship W3140860453A5021088641 @default.
• W3140860453 hasAuthorship W3140860453A5023543619 @default.
• W3140860453 hasAuthorship W3140860453A5026095888 @default.
• W3140860453 hasAuthorship W3140860453A5036477513 @default.
• W3140860453 hasAuthorship W3140860453A5068640051 @default.
• W3140860453 hasAuthorship W3140860453A5069777765 @default.
• W3140860453 hasBestOaLocation W31408604532 @default.
• W3140860453 hasConcept C111113717 @default.
• W3140860453 hasConcept C112705442 @default.
• W3140860453 hasConcept C126322002 @default.
• W3140860453 hasConcept C128544194 @default.
• W3140860453 hasConcept C142724271 @default.
• W3140860453 hasConcept C143998085 @default.
• W3140860453 hasConcept C150903083 @default.
• W3140860453 hasConcept C197934379 @default.
• W3140860453 hasConcept C207001950 @default.
• W3140860453 hasConcept C2778375690 @default.
• W3140860453 hasConcept C535046627 @default.
• W3140860453 hasConcept C71924100 @default.
• W3140860453 hasConcept C86803240 @default.
• W3140860453 hasConcept C98274493 @default.
• W3140860453 hasConceptScore W3140860453C111113717 @default.
• W3140860453 hasConceptScore W3140860453C112705442 @default.
• W3140860453 hasConceptScore W3140860453C126322002 @default.
• W3140860453 hasConceptScore W3140860453C128544194 @default.
• W3140860453 hasConceptScore W3140860453C142724271 @default.
• W3140860453 hasConceptScore W3140860453C143998085 @default.
• W3140860453 hasConceptScore W3140860453C150903083 @default.
• W3140860453 hasConceptScore W3140860453C197934379 @default.
• W3140860453 hasConceptScore W3140860453C207001950 @default.
• W3140860453 hasConceptScore W3140860453C2778375690 @default.
• W3140860453 hasConceptScore W3140860453C535046627 @default.

• next